A total of 157 patients with diverse advanced cancers with known FFPE tumor tissue mutation status for mutations in at least one of the selected cancer genes, which included BRAF, EGFR, KRAS, PIK3CA, were enrolled (Table 1). This evidence concerns the gene BRAF and cancer.